投稿信息
投稿信息
投稿命中率
審稿費用
暫無數(shù)據(jù)
版面費用
1390.0元/篇
（網(wǎng)友貢獻，非官方數(shù)據(jù)）
中國人發(fā)表比例
2023年中國人文章占該期刊總數(shù)量暫無數(shù)據(jù) (2022年為100.00%)
自引率
9.2 %
年文章數(shù)
2981
作者需知
暫無數(shù)據(jù)
NCBI查詢
偏重的研究方向
期刊簡介
稿件收錄要求
稿件收錄要求
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; www.thetcr.org) is an Open Access, peer-reviewed journal, published by AME Publishing Company, publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. TCR will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving cancer patients lives. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles. The Official Publication of Society for Translational Cancer Research (STCR),Hong Kong
常用鏈接
期刊論壇
|
中國SCI論文
|
期刊介紹
|
投稿信息
|
雜志官網(wǎng)
|
投稿鏈接
|
作者需知
|
PMC鏈接
|
Pubmed全文檢索
